Lonza and OncoMed Pharmaceuticals signed a process development and manufacturing collaboration for the latter’s anticancer monoclonal antibody candidates, and a multi-product licensing deal that will give OncoMed a license to Lonza’s GS Gene Expression System™, and Version 8 media and feeds manufacturing platform.
The facility is expected to have the same annual output as a conventional facility but in a single building.
Eli Lilly and Co. are going to invest over $700 million to enhance its global insulin manufacturing capacity in Puerto Rico, France, and China, as well as Indianapolis.
Plans are for 260,000 square feet with committed production lines.
Danaher agreed to buy GE Life Sciences biopharma business for approximately $21.4 billion cash, in a deal designed to enhance the buyer’s bioprocessing offerings and pay down the seller’s debt. Following completion of the acquisition, GE Biopharma will operate as a standalone company within Danaher’s Life Sciences segment
90,000 sq. ft. facility is to be built for the manufacture of 10 million doses/month.
Maryland firm announced birth of rhFVII transgenic rabbits at Chinese subsidiary.